RGNX
Regenxbio Inc
7.50$
-8.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -23.2% | -29.7% | +42.7% | +8.5% | -12.3% | +319.6% | -76.0% | +39.2% | +2.0% | -78.9% | +1,589.6% | – | |
| – | +25.7% | -45.7% | +72.9% | -15.3% | -49.0% | -45.6% | +165.3% | +578.4% | -90.4% | +86.8% | -90.6% | – | |
| – | -59.8% | +7.8% | +7.1% | +54.1% | +26.1% | +474.5% | -85.7% | -362.1% | – | -119.2% | – | – | |
| – | -11.8% | -1.3% | -11.5% | +21.4% | -7.4% | +5.4% | +4.7% | +0.9% | +6.3% | -3.8% | -2.2% | – | |
| – | -17.3% | -4.1% | +3.1% | +3.0% | +3.2% | +1.5% | -2.3% | +1.9% | +10.5% | -4.8% | +1.5% | – | |
| – | -13.4% | -2.3% | -7.6% | +16.0% | -10.3% | +10.8% | +2.8% | -73.1% | +303.8% | -4.1% | -1.2% | – | |
| – | – | – | – | – | – | – | -621.8% | – | – | – | – | – | |
| – | -16.1% | +44.8% | -77.2% | +82.6% | +1,048.4% | -9.0% | +28.3% | +19.8% | -6.8% | -29.1% | -10.5% | – | |
| – | – | – | – | – | – | – | -1,265.1% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -1,265.1% | – | – | – | – | – | |
| – | – | – | – | – | – | – | -400.8% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.